Mineralys Therapeutics, Inc.MLYSNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+94.7%
5Y CAGR+135.6%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+94.7%/yr
Annual compound
5Y CAGR
+135.6%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
72.5x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$38.58M+62.0%
2024$23.82M+66.6%
2023$14.30M+173.4%
2022$5.23M+116.3%
2021$2.42M+354.3%
2020$532000.00-